No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MRUS Merus
- 48.500
- +1.000+2.11%
Trading May 3 15:38 ET
2.85BMarket Cap-16166P/E (TTM)
49.500High47.990Low202.10KVolume48.500Open47.500Pre Close9.80MTurnover0.47%Turnover RatioLossP/E (Static)58.69MShares52.03552wk High7.99P/B2.09BFloat Cap18.85052wk Low--Dividend TTM43.11MShs Float52.035Historical High--Div YieldTTM3.18%Amplitude7.255Historical Low48.479Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
On April 30, Cinda Biopharmaceuticals announced the appointment of Samuel Zhang (Samuel Zhang) as the Global Chief Commercial Officer (CBO). Zhang Suhua will report to Yu Dechao, the founder, chairman and CEO of the company, who is responsible for the str
On April 30, Cinda Biopharmaceuticals announced the appointment of Samuel Zhang (Samuel Zhang) as the Global Chief Commercial Officer (CBO). Zhang Suhua will report to Yu Dechao, the founder, chairman and CEO of the company, who is responsible for the strategic planning and business development of Cinda Biotech's global business. Prior to joining Cinda Biotech, Zhang Suhua was the chief commercial officer of Genxi Biotech and NeoImmune Tech, leading the $1.2 billion acquisition partnership between Genxi Biotech and AstraZeneca. He has also held various management positions at Eli Lilly, Pfizer, Bristol-Myers Squibb, Novartis, and Merus.
Needham Reiterates Buy on Merus, Maintains $66 Price Target
Needham analyst Ami Fadia reiterates Merus with a Buy and maintains $66 price target.
Analysts Have Conflicting Sentiments on These Healthcare Companies: ZimVie Inc (ZIMV) and Merus (MRUS)
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models With High NRG1 Expression at the AACR Annual Meeting 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibo
Merus Initiated at Buy by Truist Securities
Merus Initiated at Buy by Truist Securities
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg